Final Results Part 3 of 3

AstraZeneca PLC
01 February 2007

AstraZeneca Development Pipeline

1 February 2007


Line Extensions

Compound                        Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                            MAA           NDA

Cardiovascular

Atacand                angiotensin II antagonist    diabetic retinopathy        III         2009          2009
Atacand Plus           angiotensin II antagonist /  32/12.5 mg, 32/25 mg for    III         2H 2008
                       thiazide diuretic            hypertension
Crestor                statin                       atherosclerosis             III         Filed         Filed
Crestor                statin                       outcomes CHF                III        2H 2008       2H 2008
Crestor                statin                       outcomes End Stage Renal    III         2009          2009
                                                    Disease
Seloken/Toprol-XL      beta-blocker                 HCTZ combination            III                      Approved

Gastrointestinal

Nexium                 proton pump inhibitor        NSAID GI side effects -     III      Promotable*      Filed
                                                    symptom resolution
Nexium                 proton pump inhibitor        NSAID GI side effects -     III       Launched        Filed
                                                    ulcer healing
Nexium                 proton pump inhibitor        peptic ulcer bleeding       III        1H 2008       1H 2008
Nexium Sachet          proton pump inhibitor        GERD                        III         Filed       Approved
formulation
Nexium                 proton pump inhibitor        extra-oesophageal reflux    II         >2009**       >2009**
                                                    disease

Nexium low dose        proton pump inhibitor        low dose aspirin            III         >2009         >2009
aspirin combination                                 associated peptic ulcer

Neuroscience

Seroquel SR            D2/5HT2 antagonist           schizophrenia               III         Filed         Filed
Seroquel               D2/5HT2 antagonist           bipolar maintenance         III        Q4 2007       Q2 2007
Seroquel               D2/5HT2 antagonist           bipolar depression          III        Q4 2007      Approved
Seroquel SR            D2/5HT2 antagonist           generalised anxiety         III        2H 2008       1H 2008
                                                    disorder
Seroquel SR            D2/5HT2 antagonist           major depressive            III        2H 2008       1H 2008
                                                    disorder
Seroquel SR            D2/5HT2 antagonist           bipolar mania               III        1H 2008       1H 2008

Seroquel SR            D2/5HT2 antagonist           bipolar depression          III        1H 2008       1H 2008


Oncology & Infection

Faslodex               oestrogen receptor           1st line advanced breast    III         >2009         >2009
                       antagonist                   cancer
Faslodex               oestrogen receptor           Adjuvant                    III         >2009         >2009
                       antagonist
Iressa                 EGFR-TK inhibitor            breast cancer               II          >2009         >2009

* Authorities stated these symptoms were already captured within the GERD label.
  Text stating 'No clinical interaction with naproxen or rofecoxib' was approved.

**Project Extraesophageal reflux disease (reflux asthma) will be completed but
  will not result in a regulatory filing.


       Compound                  Mechanism           Area under investigation   Phase        Estimated Filing
                                                                                            MAA           NDA

Respiratory & Inflammation

Symbicort Turbuhaler   inhaled steroid/fast onset,   Symbicort Maintenance       III       Approved
                       long-acting ss2 agonist       and Reliever Therapy for
                                                     asthma (SMART)
Symbicort pMDI         inhaled steroid/fast onset,   asthma                      III        Filed*     Approved **
                       long-acting ss2 agonist

Symbicort pMDI         inhaled steroid/fast onset,   COPD                        III        Filed*       1H 2008
                       long-acting ss2 agonist

* To be supplemented in 2008 with data supporting two additional strengths

** US approval based on 12 years and above



NCE's


Phase III


Compound                  Mechanism                 Area under                 Phase        Estimated Filing
                                                   investigation
                                                                                             MAA          NDA
Cardiovascular

AGI-1067               Anti-atherogenic              atherosclerosis            III       Q4 2007     Q2/Q3 2007
AZD6140                ADP receptor antagonist       arterial thrombosis        III        >2009        >2009
Saxagliptin (BMS)      dipeptidyl peptidase-4        diabetes                   III        >2009       1H 2008
                       (DPP-4) inhibitor

Oncology & Infection

Zactima                VEGF/EGF TKI inhibitor with   NSCLC                      III       2H 2008      2H 2008
                       RET kinase activity

Recentin (AZD2171)      VEGF signalling inhibitor                              II/III      >2009        >2009
                       (VEGFR-TKI)
                                                     NSCLC and CRC



NCE's


Phases I and II


Compound                  Mechanism           Area under investigation          Phase       Estimated Filing
                                                                                             MAA         NDA

Cardiovascular

Crestor/ABT-335        statin + fibrate fixed        dyslipidaemia                II                     2009
(Abbott)               combination
AZD9684                CPU inhibitor                 thrombosis                   II        >2009       >2009
AZD0837                thrombin inhibitor            thrombosis                   II        >2009       >2009
AZD6610                PPAR alpha with 'partial      dyslipidaemia                II        >2009       >2009
                       gamma'
Dapagliflozin (BMS)    sodium-glucose                diabetes                     II        >2009       >2009
                       cotransporter-2 (SGLT2)
                       inhibitor
AZD2479                Reverse Cholesterol Transport dyslipidaemia                I         >2009       >2009
                       enhancer
AZD1175                                              diabetes/obesity             I         >2009       >2009
AZD2207                                              diabetes/obesity             I         >2009       >2009
AZD1305                antiarrhythmic                arrhythmias                  I         >2009       >2009

Gastrointestinal

AZD9056                ion channel blocker (P2X7)    inflammatory bowel           II        >2009       >2009
                                                     disease
AZD3355                inhibitor of transient lower   GERD                        II        >2009       >2009
                       oesophageal sphincter
                       relaxations  (TLESR)

Neuroscience

PN-400 (Pozen)         naproxen + esomeprazole       Signs and symptoms of OA     II        >2009        2009
                                                     and RA

AZD3480                neuronal nicotinic receptor   cognitive disorders in       II        >2009       >2009
                       agonist                       schizophrenia
AZD3480                neuronal nicotinic receptor   Alzheimers                   II        >2009       >2009
                       agonist
AZD9272                glutamate receptor modulator  neuropathic pain             I         >2009       >2009
AZD2327                enkephalinergic receptor      anxiety & depression         I         >2009       >2009
                       modulator
AZD5904                enzyme inhibitor              multiple sclerosis           I         >2009       >2009
AZD1080                                              Alzheimers                   I         >2009       >2009
AZD3783                                              anxiety and depression       I         >2009       >2009



Phases I and II (continued)


Oncology & Infection

Zactima                VEGF/EGF TKI inhibitor with   medullary thyroid           II          2H        2H 2008
                       RET kinase activity           cancer
                                                                                            2008
CytoFab                anti-TNF-alpha polyclonal     severe sepsis               II         >2009       >2009
                       antibody
ZD4054                 endothelin A receptor         prostate cancer             II         >2009       >2009
                       antagonist
AZD5896                AGT inhibitor                 solid tumours               II         >2009       >2009
AZD6244                MEK inhibitor                 solid tumours               II         >2009       >2009
(ARRY-142886)
CAT-3888               recombinant immunotoxin hairy hairy cell leukaemia        II         >2009       >2009
                       cell
AZD0530                SRC kinase inhibitor          solid tumours and           I          >2009       >2009
                                                     haematological
                                                     malignancies
AZD1152                Aurora kinase inhibitor       solid tumours and           I          >2009       >2009
                                                     haematological
                                                     malignancies
AZD4769                                              solid tumours               I          >2009       >2009
AZD2281                PARP inhibitor                breast cancer               I          >2009       >2009
AZD4877                                              solid tumours               I          >2009       >2009
AZD1689                Hypoxia activated cytotoxic   solid tumours               I          >2009       >2009
AZD8931                                              solid tumours               I          >2009       >2009
AZD7762                                              solid tumours               I          >2009       >2009

Respiratory & Inflammation

AZD9056                ion channel blocker (P2X7)    rheumatoid arthritis        II         >2009       >2009
AZD1981                                              asthma                      II         >2009       >2009
AZD5672                                              rheumatoid arthritis        I          >2009       >2009
AZD6703                                              rheumatoid arthritis        I          >2009       >2009
AZD4818                                              COPD                        I          >2009       >2009
CAT-354                Anti-IL-13 antibody           asthma                      I          >2009       >2009


AZD5904                                              COPD                        I          >2009       >2009
AZD1744                                              asthma                      I          >2009       >2009



NCE's

Pre Clinical

Compound                  Mechanism                 Area under                 Phase        Estimated Filing
                                                   investigation
                                                                                             MAA          NDA

Cardiovascular

AZD6370                                              diabetes                    PC        >2009        >2009
AZD8593                                              haemostasis                 PC        >2009        >2009
AZD4121                cholesterol absorption        dyslipidaemia               PC        >2009        >2009
                       inhibitor
AZD1283                                              thrombosis                  PC        >2009        >2009

AZD5861                                              dyslipidaemia               PC        >2009        >2009

AZD1656                                              diabetes/obesity            PC        >2009        >2009

AZD3988                                              diabetes/obesity            PC        >2009        >2009


Gastrointestinal

AZD2066                                              GERD                        PC        >2009        >2009

AZD5329                                              functional GI disease       PC        >2009        >2009


Neuroscience

AZD3102                                              Alzheimers                  PC        >2009        >2009
AZD6538                                              neuropathic pain            PC        >2009        >2009
AZD8797                                              multiple sclerosis          PC        >2009        >2009
AZD1940                                              nociceptive and             PC        >2009        >2009
                                                     neuropathic pain.
AZD3241                                              Parkinson's disease         PC        >2009        >2009
AZD2066                                              analgaesia                  PC        >2009        >2009
AZD6280                                              anxiety                     PC        >2009        >2009
AZD1386                                              analgaesia                  PC        >2009        >2009
AZD2624                                              schizophrenia               PC        >2009        >2009
AZD0328                                              Alzheimers                  PC        >2009        >2009
AZD3043                GABA-A receptor modulator     short acting                PC        >2009        >2009
                                                     anaesthetic
AZD7903                                              analgaesia                  PC        >2009        >2009



Pre Clinical (continued)


Compound                         Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation
                                                                                             MAA          NDA
Oncology & Infection

AZD9935                VEGF signalling inhibitor     solid tumours               PC        >2009        >2009
                       (VEGFR-TKI)
AZD0424                SRC kinase inhibitor          solid tumours               PC        >2009        >2009
AZD5180                anti-angiogenic               solid tumours               PC        >2009        >2009
AZD1845                                              solid tumours               PC        >2009        >2009
AZD8330                                              solid tumours               PC        >2009        >2009
AZD3646                                              solid tumours and           PC        >2009        >2009
                                                     haematological
                                                     malignancies
AZD9468                                              solid tumours               PC        >2009        >2009

AZD2932                                              solid tumours               PC        >2009        >2009

AZD4992                                                                          PC        >2009        >2009

CAT-8015               recombinant immunotoxin       haematological              PC        >2009        >2009
                                                     malignancies
CAT-5001               recombinant immunotoxin       solid tumours               PC        >2009        >2009

AZD6918                                              solid tumours               PC        >2009        >2009

AZD5099                                              infection                   PC        >2009        >2009

Respiratory & Inflammation

AZD6067                protease inhibitor            COPD                        PC        >2009        >2009
AZD6357                                              osteoarthritis              PC        >2009        >2009
AZD7928                                              COPD                        PC        >2009        >2009
AZD2392                                              asthma                      PC        >2009        >2009
AZD3825                                              asthma                      PC        >2009        >2009
AZD1236                                              COPD                        PC        >2009        >2009
AZD5069                                              COPD                        PC        >2009        >2009
AZD9668                                              COPD                        PC        >2009        >2009
AZD9215                                              asthma                      PC        >2009        >2009
AZD1678                                              asthma                      PC        >2009        >2009
AZD8848                                              asthma                      PC        >2009        >2009
AZD8075                                              asthma                      PC        >2009        >2009
AZD6605                                              osteoarthritis              PC        >2009        >2009
CAM-3001                                             rheumatoid arthritis        PC        >2009        >2009
AZD3199                                              asthma/COPD                 PC        >2009        >2009




AstraZeneca Development Pipeline
Discontinued Projects vs 8 June ABR


Cardiovascular & Gastrointestinal

NCE/Line Extension           Compound                        Area under investigation

NCE                          AZD8677                         dyslipidaemia/diabetes
NCE                          AZD7009                         atrial fibrillation conversion
NCE                          AZD8450                         dyslipidaemia
NCE                          AZD8081                         functional GI disease
NCE                          AZD9272                         GERD
NCE                          AZD9335                         GERD



Neuroscience

NCE/Line Extension          Compound                         Area under investigation

NCE                         NXY-059                          stroke
NCE                         AZD9272                          anxiety
NCE                         AZD9335                          neuropathic pain
NCE                         AZD7512                          depression & anxiety



Oncology and Infection

NCE/Line Extension          Compound                         Area under investigation

Line Extension              Faslodex                         2nd line after aromatase
                                                             inhibitor faliure
Line Extension              Iressa                           Head & Neck



Respiratory and Inflammation

NCE/Line Extension          Compound                         Area under investigation

NCE                         AZD8955                          OA
NCE                         AZD9056                          COPD
NCE                         AZD8309                          RA
NCE                         AZD8309                          COPD
NCE                         AZD3342                          COPD


Comments

As disclosure of compound information is balanced by the business need to
maintain confidentiality, information in relation to some compounds listed here
has not been disclosed at this time.


Compounds in development are displayed by phase.


Abbreviations:


PC - Pre-clinical: Candidate Drug accepted for development but not yet
                   administered to man.

MAA - Marketing Authorisation Application (Europe).

NDA - New Drug Application (USA).

                      This information is provided by RNS
            The company news service from the London Stock Exchange